Clinical trial · Observational
Mass Spectral Fingerprinting in Lung Cancer
Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Lung Cancer
NCT02781857CI-TRIAL-00113208completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To answer the question whether a disease specific profile of breath in patients with lung cancer can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 100 patients with lung cancer
- description
- * Group A: 70 patients with any type of lung cancer eligible for lung cancer surgery * Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma).
- interventionNames
- Other: No intervention
- label
- 60 controls
- description
- 60 controls (group C) matched for age, gender, smoking history.
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- Concentration of volatile organic compounds (VOCs) in the exhaled breath will be analysed using mass spectrometry
- timeFrame
- 1 day, single measurement
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed lung cancer based on cytological or histological analysis. * Group A: any type of lung cancer eligible for surgical resection (up to TNM stage IIIa). * Group B: any type of lung cancer (small-cell carcinoma, non-small-cell carcinoma) not amenable for surgical resection. * Group C: matched controls. * Age between 18 and 85 years at study entry Exclusion Criteria: * Another 'active' secondary malignant disease (e.g. breast cancer, colon carcinoma) in group A and B, presence of any active malignant disease in group C (based on personal information). * Acute inflammatory disease (e.g. common cold) within the last 4 weeks. * Any other acute lung disease which affects breath measurements * Acute or chronic hepatic disease. * Renal failure or renal replacement therapy.
References
Publications (2)
- DERIVEDFricke K, Herth J, Baur DM, Sievi NA, Schmidt F, Gaisl T, Steinack C, Ulrich S, Kohler M. Real-time breath metabolomic profiling reveals a volatile signature associated with lung cancer. Biomed Pharmacother. 2026 Aug 6;202:119835. doi: 10.1016/j.biopha.2026.119835. Online ahead of print. PMID 42561601
- DERIVEDHerth J, Schmidt F, Basler S, Sievi NA, Kohler M. Exhaled breath analysis in patients with potentially curative lung cancer undergoing surgery: a longitudinal study. J Breath Res. 2024 May 17;18(3). doi: 10.1088/1752-7163/ad48a9. PMID 38718786